BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 37 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $38,000 | -35.6% | 10,000 | -23.1% | 0.00% | -40.0% |
| Q4 2020 | $59,000 | -73.2% | 13,000 | 0.0% | 0.01% | -77.3% |
| Q3 2020 | $220,000 | +50.7% | 13,000 | 0.0% | 0.02% | +10.0% |
| Q2 2020 | $146,000 | +143.3% | 13,000 | 0.0% | 0.02% | +122.2% |
| Q1 2020 | $60,000 | +7.1% | 13,000 | 0.0% | 0.01% | +28.6% |
| Q4 2019 | $56,000 | +9.8% | 13,000 | 0.0% | 0.01% | 0.0% |
| Q3 2019 | $51,000 | -25.0% | 13,000 | -24.9% | 0.01% | -30.0% |
| Q2 2019 | $68,000 | -9.3% | 17,300 | 0.0% | 0.01% | -16.7% |
| Q1 2019 | $75,000 | +63.0% | 17,300 | +33.1% | 0.01% | +33.3% |
| Q4 2018 | $46,000 | +9.5% | 13,000 | +18.2% | 0.01% | 0.0% |
| Q3 2018 | $42,000 | -2.3% | 11,000 | 0.0% | 0.01% | -18.2% |
| Q2 2018 | $43,000 | +48.3% | 11,000 | +22.2% | 0.01% | +37.5% |
| Q1 2018 | $29,000 | -6.5% | 9,000 | 0.0% | 0.01% | 0.0% |
| Q4 2017 | $31,000 | – | 9,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 2,500 | $825,000 | 0.55% |
| SABBY MANAGEMENT, LLC | 136,484 | $27,310 | 0.02% |
| LIBERTY WEALTH MANAGEMENT LLC | 352,619 | $71 | 0.02% |
| Weaver Consulting Group | 99,356 | $19,881 | 0.01% |
| ABNER HERRMAN & BROCK LLC | 145,500 | $29 | 0.00% |
| JMAC ENTERPRISES LLC | 65,430 | $13,093 | 0.00% |
| Professional Financial Advisors, LLC | 17,279 | $3,458 | 0.00% |
| Ikarian Capital, LLC | 90,242 | $18,057 | 0.00% |
| MOORE CAPITAL MANAGEMENT, LP | 200,000 | $40,020 | 0.00% |
| Weaver Consulting Group | 45,000 | $2,750 | 0.00% |